Literature DB >> 6683591

Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma.

P F Engstrom, P T Lavin, D J Klaassen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6683591

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  11 in total

Review 1.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the small intestines, gallbladder, liver, and esophagus.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-08       Impact factor: 1.798

2.  Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.

Authors:  Elisabeth I Heath; Susan Urba; John Marshall; Steven Piantadosi; Arlene A Forastiere
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

3.  13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.

Authors:  C F Slabber; G Falkson; W Burger; L Schoeman
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.

Authors:  Joanne F Rossman; Carla I Falkson; Ronghui Xu; Coenraad F Slabber; Bernard A Mason; Mary F Mulcahy; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2011-01

5.  Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus.

Authors:  A Harstrick; C Bokemeyer; P Preusser; C H Köhne-Wömpner; H J Meyer; M Stahl; H Knipp; H J Schmoll; H Wilke
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Current management of esophageal squamous-cell carcinoma in Japan and other countries.

Authors:  Katsuhiko Higuchi; Wasaburo Koizumi; Satoshi Tanabe; Tohru Sasaki; Chikatoshi Katada; Mizutomo Azuma; Kento Nakatani; Kenji Ishido; Akira Naruke; Takahiro Ryu
Journal:  Gastrointest Cancer Res       Date:  2009-07

7.  Trimetrexate in advanced carcinoma of the esophagus.

Authors:  A S Alberts; G Falkson; M Badata; A P Terblanche; E U Schmid
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

8.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Authors:  T C Kok; A Van der Gaast; J Dees; W M Eykenboom; H Van Overhagen; G Stoter; H W Tilanus; T A Splinter
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

9.  Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus.

Authors:  Tomonori Nakanoko; Hiroshi Saeki; Masaru Morita; Yuichiro Nakashima; Koji Ando; Eiji Oki; Takefumi Ohga; Yoshihiro Kakeji; Yasushi Toh; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2013-09-25       Impact factor: 5.344

10.  Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial.

Authors:  Yoshitomo Yanagimoto; Shuji Takiguchi; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Hiroshi Hosoda; Kenji Kangawa; Masaki Mori; Yuichiro Doki
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.